A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2011
12/29/2011	WO2011163499A2 Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
12/29/2011	WO2011163469A1 Hydrated form of anti-inflammatory roflumilast-n-oxide
12/29/2011	WO2011163452A2 Treating surface of the eye disorders
12/29/2011	WO2011163436A1 Double stranded rna compounds to rhoa and use thereof
12/29/2011	WO2011163430A1 Polymorphs of osi-906
12/29/2011	WO2011163389A2 Method for inducing fat loss in mammals
12/29/2011	WO2011163358A2 Intravaginal devices comprising anticholinergic agents, and methods of making thereof
12/29/2011	WO2011163356A2 Methods of treating conditions associated with overactive bladder
12/29/2011	WO2011163355A1 Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
12/29/2011	WO2011163321A2 Composition and method of treating lipid encapsulated virus infections
12/29/2011	WO2011163319A2 Activation of amp-protein activated kinase by oxaloacetate compounds
12/29/2011	WO2011163308A2 Compositions and methods for preventing and treating organ injury and/or dysfunction
12/29/2011	WO2011163280A1 Indole compounds as positive allosteric modulators of the muscarinic receptor
12/29/2011	WO2011163241A2 Neuroprotective compounds
12/29/2011	WO2011163231A2 Combination therapy for the treatment of diabetes
12/29/2011	WO2011163222A1 Nilotinib salts and crystalline forms thereof
12/29/2011	WO2011163206A2 Controlled release compositions with reduced food effect
12/29/2011	WO2011163198A2 Tg2 inhibitors and uses thereof
12/29/2011	WO2011163195A1 Fused pyrrole derivatives as pi3k inhibitors
12/29/2011	WO2011163090A1 Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
12/29/2011	WO2011163085A2 Method and compositions use for endothelin-1 related kidney diseases
12/29/2011	WO2011163029A2 Alkenyl substituted cycloaliphatic compounds as chemical inducers of proximity
12/29/2011	WO2011162951A1 Compositions and methods for enhancing reduction of spore-forming microorganism
12/29/2011	WO2011162835A1 Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
12/29/2011	WO2011162752A1 Topical ophthalmic suspensions containing tobramycin and dexamethasone
12/29/2011	WO2011162733A1 Antibacterial and/or antifungal component having the property of binding specifically to bacteria and/or fungi
12/29/2011	WO2011162639A1 Heterochain aliphatic poly-n-oxide copolymers and vaccinating agents and drugs based thereon
12/29/2011	WO2011162633A1 Soft cationic mitochondrial uncouplers
12/29/2011	WO2011162562A2 [6+5] fused bicycles as a thrombin antagonist, process for preparation thereof and pharmaceutical compositions containing the bicycles
12/29/2011	WO2011162560A2 Pharmaceutical composition in which solubility of partially soluble tricyclic derivative is improved
12/29/2011	WO2011162515A2 Novel fused pyrimidine derivatives for inhd3ition of tyrosine kinase activity
12/29/2011	WO2011162480A2 Composition for treating prion diseases comprising hif-1α agonist
12/29/2011	WO2011162419A1 Tumor growth controlling method targeting galactosylceramide expression factor-1
12/29/2011	WO2011162416A1 Agent for suppressing the formation of abnormal skin cells caused by exposure to light
12/29/2011	WO2011162409A1 Compounds having trpv1 antagonistic activity and uses thereof
12/29/2011	WO2011162390A1 Sustained-release therapeutic agent for hypertension and renal dysfunction
12/29/2011	WO2011162368A1 Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
12/29/2011	WO2011162343A1 Antitumor agent using compounds having kinase inhibitory effect in combination
12/29/2011	WO2011162320A1 Combination of egcg or methylated egcg and a pde inhibitor
12/29/2011	WO2011162300A1 Crystal of fused pyridine compound salt
12/29/2011	WO2011162274A1 Isoquinoline derivative
12/29/2011	WO2011162267A1 Novel thiophenecarboxamide derivatives and use thereof as medicine
12/29/2011	WO2011162234A1 Composition which is used for purpose of inhibiting biosynthesis of cholesterol
12/29/2011	WO2011162222A1 Novel crystalline forms of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1h-indole-1,3-diyl]dibutanoic acid, 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutanoic acid, and 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutanoic acid
12/29/2011	WO2011161964A1 Agent for improving insulin resistance with acat inhibitor as active component
12/29/2011	WO2011161690A1 Processes for the preparation of (+)-n,n-dimethyl-2-[1-(naphthalenyloxy) ethyl] benzene methanamine and intermediates thereof
12/29/2011	WO2011161689A1 Imatinib mesilate pharmaceutical tablet
12/29/2011	WO2011161687A1 Process for preparing extra pure 2, 6-diisopropyl phenol
12/29/2011	WO2011161645A1 5-lipoxygenase inhibitors
12/29/2011	WO2011161644A1 Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
12/29/2011	WO2011161631A2 Compounds for treatment of tumors bearing deregulated myc oncoproteins
12/29/2011	WO2011161615A1 5-lipoxygenase inhibitors
12/29/2011	WO2011161537A2 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof
12/29/2011	WO2011161521A1 Compositions comprising metformin and rosiglitazone
12/29/2011	WO2011161504A1 Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof
12/29/2011	WO2011161501A2 Solid compositions in form of powders or granulates for the oral administration of active ingredients and method for obtaining them
12/29/2011	WO2011161484A1 Use of an estrogen derivative for the manufacture of pharmaceutical compositions useful for the treatment and/or prevention of psychiatric diseases and for the treatment and prevention of said diseases
12/29/2011	WO2011161446A1 Compounds for treating proliferative disorders
12/29/2011	WO2011161439A1 Pharmaceutical composition comprising midazolam
12/29/2011	WO2011161421A1 Salts and polymorphs of dexrabeprazole
12/29/2011	WO2011161282A1 Use of rapamycin for the treatment of the cognitive deficits associated with down's syndrome
12/29/2011	WO2011161274A1 Procedure for the obtainment of fatty acids of pharmacological and nutritional interest
12/29/2011	WO2011161256A1 Beta carboline derivatives useful in the treatment of proliferative disorders
12/29/2011	WO2011161249A1 Use of 1h-quinazoline-2,4-diones
12/29/2011	WO2011161245A2 Polymorphs of an active pharmaceutical ingredient
12/29/2011	WO2011161236A1 Stabilized active compound
12/29/2011	WO2011161235A1 Semuloparin for use as an antithrombotic treatment in hip replacement surgery with improved safety in terms of clinically relevant bleedings
12/29/2011	WO2011161234A1 Semuloparin for the extended prevention of a mortality and/or morbidity event in a patient having undergone hip fracture surgery
12/29/2011	WO2011161228A1 Semuloparin for the prevention of a mortality and/or morbidity event in a patient undergoing major orthopaedic surgery
12/29/2011	WO2011161223A2 Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
12/29/2011	WO2011161216A1 Heteroaryl compounds and compositions as protein kinase inhibitors
12/29/2011	WO2011161209A1 Injectable formulation of a macrocyclic lactone and levamisole
12/29/2011	WO2011161201A1 Bisarylsulfonamides useful as kinase inhibitors in the treatment of inflammation and cancer
12/29/2011	WO2011161161A1 Diabetes therapy
12/29/2011	WO2011161159A1 Heterocyclic compounds, their preparation and their therapeutic application
12/29/2011	WO2011161151A1 Use of dibenzofuranone derivatives to inhibit kinases
12/29/2011	WO2011161128A1 Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
12/29/2011	WO2011161123A2 Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
12/29/2011	WO2011161101A1 6,7-dihydro-5h-benzo[7]annulene derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and the use thereof for production of medicaments
12/29/2011	WO2011161099A1 Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
12/29/2011	WO2011161065A1 Macrocyclic tetrapyrrolic compound of the family of porphyrins, chlorins and bacteriochlorins as photosensitizers for photodynamic therapy
12/29/2011	WO2011161055A1 Dialysis precursor composition
12/29/2011	WO2011161053A1 Prebiotic effect of galactofructose
12/29/2011	WO2011161035A1 3-aryl-4-(2-thienylmethylene)-isoxazol-5(4h)-ones as fungicides
12/29/2011	WO2011161031A1 Benzotriazolodiazepine compounds inhibitors of bromodomains
12/29/2011	WO2011161030A1 Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
12/29/2011	WO2011161018A1 Alkaloid aminoester derivatives and medicinal compositions thereof
12/29/2011	WO2011161009A1 Anellated pyridine compounds as dual modulators of the 5-ht2a and d3 receptors
12/29/2011	WO2011161008A1 Quinolizidine and indolizidine derivatives
12/29/2011	WO2011161006A1 Amido-tropane derivatives
12/29/2011	WO2011160974A2 Statin derivatives
12/29/2011	WO2011160920A1 Dry powder formulation comprising an antimuscarinic drug
12/29/2011	WO2011160919A1 Alkaloid aminoester derivatives and medicinal composition thereof
12/29/2011	WO2011160918A1 Alkaloid aminoester derivatives and medicinal composition thereof
12/29/2011	WO2011160845A2 Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment
12/29/2011	WO2011160844A1 Agent for the treatment of skin conditions
12/29/2011	WO2011160839A1 Neramexane multiple unit dosage form
12/29/2011	WO2011160823A1 Combination of d-amino acids and phenylbutyric acid
12/29/2011	WO2011160822A1 Organic salts and co-crystals of phenylbutyric acid of d-amino acids
12/29/2011	WO2011160821A2 Organic salts and co-crystals of phenylbutyric acid

1 ... 1415 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 ... 7860